Clearside Biomedical/$CLSD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Clearside Biomedical
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Ticker
$CLSD
Sector
Primary listing
Employees
32
Headquarters
Website
CLSD Metrics
BasicAdvanced
$18m
-
-$5.05
1.87
-
Price and volume
Market cap
$18m
Beta
1.87
52-week high
$0.47
52-week low
$0.31
Financial strength
Current ratio
2.98
Quick ratio
2.551
Long term debt to equity
-113.492
Total debt to equity
-114.204
Interest coverage (TTM)
-2.17%
Profitability
EBITDA (TTM)
-22.63
Gross margin (TTM)
88.07%
Net profit margin (TTM)
-780.90%
Operating margin (TTM)
-689.76%
Effective tax rate (TTM)
-2.83%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-70.35%
Return on equity (TTM)
58.59%
Valuation
Price to revenue (TTM)
0.495
Price to book
-0.29
Price to tangible book (TTM)
-0.29
Price to free cash flow (TTM)
-0.076
Free cash flow yield (TTM)
-1,321.00%
Free cash flow per share (TTM)
-4.22
Growth
Revenue change (TTM)
-56.78%
Earnings per share change (TTM)
-25.68%
3-year revenue growth (CAGR)
-50.03%
3-year earnings per share growth (CAGR)
64.02%
10-year earnings per share growth (CAGR)
-26.30%
What the Analysts think about CLSD
Analyst ratings (Buy, Hold, Sell) for Clearside Biomedical stock.
CLSD Financial Performance
Revenues and expenses
CLSD Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.